Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KRONOS BIO, INC.

(KRON)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kronos Bio : Piper Sandler Starts Kronos Bio at Overweight With $50 Price Target

11/03/2020 | 08:35am EST


© MT Newswires 2020
All news about KRONOS BIO, INC.
11/24Kronos Bio Announces Participation in Upcoming Investor Conferences
AQ
11/12KRONOS BIO : Management Change/Compensation - Form 8-K/A
PU
11/12KRONOS BIO, INC. Change in Directors or Principal Officers (form 8-K/A)
AQ
11/12KRONOS BIO, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
11/11Kronos Bio Appoints Roshawn Blunt to Board of Directors
GL
11/11Kronos Bio Appoints Roshawn Blunt to Board of Directors
CI
11/09Kronos Bio Reports Recent Business Progress and Third-Quarter Financial Results - Form ..
PU
11/09Kronos Bio Narrows Q3 Net Loss From Year-Ago Levels
MT
11/09KRONOS BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
11/09Kronos Bio Reports Recent Business Progress and Third-Quarter Financial Results
AQ
More news
Analyst Recommendations on KRONOS BIO, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -144 M - -
Net cash 2021 178 M - -
P/E ratio 2021 -4,52x
Yield 2021 -
Capitalization 693 M 693 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 95
Free-Float 83,1%
Chart KRONOS BIO, INC.
Duration : Period :
Kronos Bio, Inc. Technical Analysis Chart | KRON | US50107A1043 | MarketScreener
Technical analysis trends KRONOS BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 12,29 $
Average target price 43,00 $
Spread / Average Target 250%
EPS Revisions
Managers and Directors
Norbert W. Bischofberger President, Chief Executive Officer & Director
Yasir B. Al-Wakeel CFO & Head-Corporate Development
Arie S. Belldegrun Chairman
Jorge DiMartino Chief Medical Officer & EVP-Clinical Development
Christopher Dinsmore Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
KRONOS BIO, INC.-58.86%693
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431